ClinicalTrials.gg
CompletedNCT07137689Updated Apr 23, 2026

A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function

A Phase 1 interventional study of LY3537982 in Renal Insufficiency, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Renal Insufficiency by Eli Lilly and Company — 1 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Eli Lilly and Company.

Enrollment
4th of 12
32 · median 30
Started
2025
with 1 other
Phase 1
12 of 12
1 open now
Registered
9th of 12
by date

Among the 12 studies in Renal Insufficiency by Eli Lilly and Company, this one is the 4th largest by enrollment, is one of 2 that started in 2025, is one of 12 in phase 1, and was the 9th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

1 of the 12 studies in Renal Insufficiency by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Renal Insufficiency by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to help determine the right dose of LY3537982 in participants with kidney problems, particularly those with severe kidney problems. The study will last about 43 days for each participant.

03

Conditions studied

  • Renal Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) within the range 19.0 to 42.0 kilograms per square meter (kg/m²), inclusive.
  • Participants Assigned Male at Birth (AMAB) who agree to follow guidance or participants AFAB who are individuals of (INOCBP).
  • Severe renal impairment: Have determined by CKD-EPI of less than 30 mL/min and not requiring dialysis.
  • Moderate renal impairment: Have eGFR determined by CKD-EPI of greater than or equal to 30 mL/min and less than 60 mL/min.
  • Are not currently or have not previously been on hemodialysis, including peritoneal dialysis.
  • Have acceptable blood pressure as defined by systolic blood pressure less than 160 mmHg and diastolic blood pressure less than 95 mmHg, as well as acceptable pulse rate as defined by no less than 50 bpm and no greater than 100 bpm

Exclusion criteria

Exclusion Criteria:

  • Have history of chronic liver disease, or any evidence for hepatic impairments, or

    * or AST greater than 2.5 × without any increase in TBL or * TBL greater than 1.5 × ULN without any increase in aminotransferase.

  • Have a current, functional renal transplant. Non-functional renal allografts may be allowed if failure has been greater than 1 year and no longer on therapies.
  • Diagnosed and/or treated within 5 years prior to screening with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and curatively resected in situ carcinoma of the cervix
  • Have known allergies to LY3537982, related compounds or any components of the formulation, or a history of significant atopy.
  • Have previously completed or withdrawn from this study or any other study investigating LY3537982.
  • Have participated, within the last 30 days, in a clinical study involving an product. If the previous investigational product has a long half-life, 5 half-lives or 30 days, whichever is longer should have passed, prior to admission
  • Show evidence of infection or positive human HIV antibodies.
  • Have evidence of at screening, that is, positive test for hepatitis B surface antigen, HBV DNA, or both.
  • Have a positive antibody test. Participants with a positive hepatitis C antibody test at screening can be included only if a confirmatory HCV RNA test is negative.
  • Are participants AFAB with a positive pregnancy test or who are lactating. ssion onward, up to 2 g per day of acetaminophen will be allowed at the discretion of the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    LY3537982 (Normal renal function)

    LY3537982 administered orally.

    Drug: LY3537982

  • Experimental
    LY3537982 (Severe renal impairment)

    LY3537982 administered orally.

    Drug: LY3537982

  • Experimental
    LY3537982 (Moderate renal impairment)

    LY3537982 administered orally.

    Drug: LY3537982

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Maximum Concentration (Cmax) of LY3537982

    Time frame: Day 1, Predose up to Day 5 Postdose

  2. Pharmacokinetics: Area Under the Concentration Verses Time Curve from Time Zero to Infinity (AUC[0-∞]) of LY3537982

    Time frame: Day 1, Predose up to Day 5 Postdose

  3. Pharmacokinetics: Area Under the Concentrations Verses Time Curve from Time Zero to Time t (AUC(0-tlast) of LY3537982

    Time frame: Day 1, Predose up to Day 5 Postdose

07

Study locations

4 sites
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Panax Clinical Research
    Miami Lakes, Florida 33014, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Genesis Clinical Research
    Tampa, Florida 33603, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Apr 2026, 7 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2025
First posted
Aug 22, 2025
StartActual
Aug 18, 2025
Primary completionActual
Apr 10, 2026
CompletionActual
Apr 10, 2026
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07137689
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Aug 18, 2025
Primary completion
Apr 10, 2026
Completion
Apr 10, 2026
Last update
Apr 23, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olomorasib

Start the discussion